Senator Ron Wyden (D-Ore.), a senior member of the Senate Finance Committee, accused Pfizer (PFE) of carrying out what he ...

Reporting zero taxable profits in the U.S. in 2019, Pfizer (NYSE:PFE) carried out possibly the largest tax-avoidance scheme ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Citi analyst Geoff Meacham keeps a Neutral rating on Pfizer (PFE) with a $27 price target after the Wall Street Journal reported that U.S.

Robert F. Kennedy Jr. is set to significantly cut the size of HHS, reshaping the nation’s health agencies and closing ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

However, Pfizer's foundation remains solid, based on strong cash flow generated from a diverse basket of drugs. The company's large size confers significant competitive advantages in developing ...